Daily conventionally fractionated radiotherapy probably leads to higher overall survival compared with no radiotherapy (supportive care alone) (moderate certainty).
Anti‐angiogenic drugs plus chemotherapy probably leads to lower overall survival† compared with chemotherapy (moderate certainty).
Dinutuximab‐containing immunotherapy probably leads to lower overall survival (reported as mortality) compared with standard therapy (moderate certainty).
FOLFIRI + targeted therapy leads to lower overall survival compared with FOLFIRI (high certainty).
EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy showed no clear difference in overall survival compared with chemotherapy alone (low certainty).
Modern chemotherapy regimens probably leads to lower overall survival compared with 5‐flourouracil (moderate certainty).
Summary of findings table ‐ Daratumumab plus standard therapy probably leads to lower overall survival (at 36 months) compared with standard therapy (moderate certainty).
Chemotherapy with bevacizumab leads to lower overall survival (OS) compared with chemotherapy alone (high certainty).
Irinotecan + targeted therapy showed no clear difference in overall survival compared with irinotecan (low certainty).
Anti‐CTLA4 monoclonal antibodies plus chemotherapy showed no clear difference in overall survival† compared with chemotherapy (low certainty).
Anti‐CD20 mAb maintenance therapy showed no clear difference in overall survival compared with observation (moderate certainty).
Hormone replacement therapy (HRT) may leads to lower overall survival compared with no HRT (low certainty).
Immunomodulatory drug maintenance therapy showed no clear difference in overall survival compared with placebo/observation (moderate certainty).
Summary of findings 1: PLD with chemotherapy showed no clear difference in overall survival (OS) compared with alternative combination chemotherapy (moderate certainty).
It is very uncertain whether surgery plus whole brain radiotherapy (WBRT) changes overall survival compared with stereotactic radiosurgery (very low certainty).
Surgery plus whole brain radiotherapy (WBRT) showed no clear difference in overall survival compared with stereotactic radiosurgery plus WBRT (low certainty).
Post‐surgical chemotherapy leads to lower overall Survival (OS) compared with surgery alone (high certainty).
Chemotherapy with TKI followed by TKI maintenance showed no clear difference in overall survival (OS) compared with chemotherapy alone (low certainty).
Chemotherapy with TKI (peptide‐Fc fusion protein) showed no clear difference in overall survival (OS) compared with chemotherapy alone (moderate certainty).